Case studies · Paediatrics · 3 November 2026

Meningococcal meningitis case study

The case

Patient: A 4‑year‑old boy, previously well, presents to the emergency department with a 12‑hour history of fever, irritability and a rapidly worsening rash.

Presenting complaint: Fever (up to 39.8 °C) and a non‑pruritic, petechial rash that began on the trunk and spread to the limbs. The mother reports that the child has been increasingly lethargic, is refusing to drink, and has had two episodes of vomiting.

History:

• Onset: Sudden onset of high‑grade fever 12 h ago, followed by headache (inferred from crying when the head is touched) and neck stiffness noted by the mother.
• Past medical history: Up‑to‑date immunizations, including the first dose of Men‑C conjugate vaccine at 12 months. No known chronic illnesses.
• Family/social history: Lives in a crowded urban apartment with two older siblings who are well. No recent travel. No known sick contacts.
• Drug history: No regular medications. Received paracetamol at home with minimal effect.

Examination:

• General: Ill‑appearing, irritable, lying supine, refusing to be held.
• Vital signs:
  • Temperature: 39.8 °C (oral)
  • Heart rate: 138 bpm (age‑appropriate tachycardia)
  • Respiratory rate: 28 /min (mild tachypnoea)
  • Blood pressure: 92/58 mm Hg (borderline low for age)
  • Oxygen saturation: 96 % on room air
• Head & neck: Bulging anterior fontanelle (soft spot still open), neck stiffness, positive Kernig’s sign, positive Brudzinski’s sign.
• Skin: Diffuse non‑blanching petechial rash, 1–2 mm in diameter, most dense on the trunk and lower limbs; no purpura fulminans at this stage.
• Neurological: Glasgow Coma Scale (GCS) 13 (E4 V4 M5); pupils equal, reactive; no focal deficits.
• Cardiovascular & respiratory: Normal heart sounds, clear lungs.

Initial investigations (drawn before antibiotics):

The child is transferred to the pediatric intensive care unit (PICU) for close monitoring and further management.

Questions

1. What is the most likely diagnosis?
2. Which clinical and laboratory findings specifically point toward this diagnosis, and why?
3. List the immediate investigations that should be performed in a suspected case of bacterial meningitis in a child, and explain the rationale for each.
4. Outline the evidence‑based acute management plan, including antimicrobial therapy, supportive measures, and adjunctive treatment.
5. Discuss the possible short‑ and long‑term complications of meningococcal meningitis and the strategies for prevention of disease transmission and recurrence.

Answers

1. What is the most likely diagnosis?

Meningococcal meningitis caused by Neisseria meningitidis (most likely serogroup C in this scenario).

Rationale: The child presents with the classic triad of acute bacterial meningitis—fever, neck stiffness, and altered mental status—plus a petechial rash, which is highly suggestive of meningococcal infection. The CSF analysis shows a markedly elevated opening pressure, turbid appearance, neutrophilic pleocytosis (>1 000 cells/µL), high protein, and low glucose, all typical of bacterial meningitis. The rapid antigen test confirming N. meningitidis solidifies the diagnosis.

2. Which clinical and laboratory findings specifically point toward this diagnosis, and why?

Together, these findings create a pattern that is highly specific for meningococcal meningitis.

3. List the immediate investigations that should be performed in a suspected case of bacterial meningitis in a child, and explain the rationale for each.

All investigations should be performed promptly; however, antibiotic therapy must not be delayed while awaiting results.

4. Outline the evidence‑based acute management plan, including antimicrobial therapy, supportive measures, and adjunctive treatment.

A. Empiric antimicrobial therapy (started immediately after blood cultures, before LP if possible):

Rationale: Ceftriaxone achieves high CSF concentrations and covers N. meningitidis, H. influenzae and susceptible S. pneumoniae. Vancomycin is added empirically to cover resistant S. pneumoniae until sensitivities are known.

B. Adjunctive therapy:

• Dexamethasone 0.15 mg/kg IV every 6 h, started before or with the first dose of antibiotics and continued for 4 days. Evidence (NEJM 2020, IDSA 2023) shows reduced hearing loss and neurological sequelae, especially in H. influenzae and S. pneumoniae meningitis; still recommended for meningococcal meningitis in children.

C. Supportive care:

1. Airway, Breathing, Circulation (ABCs): Secure airway if GCS < 8, provide supplemental O₂ to keep SpO₂ > 94 %.
2. Fluid resuscitation: 20 mL/kg isotonic saline bolus over 15 min; repeat as needed to maintain MAP ≥ 50 mm Hg and urine output ≥ 1 mL/kg/h.
3. Management of raised ICP: Elevate head of bed 30°, avoid hyperventilation, consider mannitol 0.5 g/kg IV bolus if ICP signs persist.
4. Temperature control: Paracetamol 15 mg/kg IV/PO q6h; consider external cooling if >40 °C.
5. Seizure prophylaxis: If seizures occur, treat with levetiracetam 20 mg/kg IV loading dose, then 10 mg/kg q12h. Routine prophylaxis is not recommended.
6. Monitoring: Hourly neuro checks, continuous pulse oximetry, cardiac telemetry, invasive blood pressure if unstable.

D. Isolation and infection control:

• Droplet precautions (surgical mask for staff, patient in a single room) for at least 24 h after the first dose of effective antibiotics.

E. Chemoprophylaxis for close contacts:

• Rifampicin 10 mg/kg PO once daily for 2 days (max 600 mg per dose) OR Ciprofloxacin 20 mg/kg PO single dose (max 500 mg) for household contacts and anyone with prolonged close exposure.

F. Follow‑up investigations:

• Repeat CSF culture at 48 h if initial culture negative.
• Serial CBC, CRP, electrolytes, and coagulation profile daily for the first 3 days.

G. Discharge criteria:

• Afebrile ≥ 48 h, stable vitals, improving neurological status, able to tolerate oral intake, and completed at least 7 days of appropriate antibiotics.

5. Discuss the possible short‑ and long‑term complications of meningococcal meningitis and the strategies for prevention of disease transmission and recurrence.

Short‑term complications (within the first 2 weeks):

Long‑term complications (months to years):

• Neurocognitive deficits (learning difficulties, attention deficits).
• Motor deficits (cerebral palsy, spasticity).
• Chronic hearing impairment requiring hearing aids or cochlear implants.
• Visual impairment (optic atrophy).
• Psychiatric sequelae (anxiety, depression).

Prevention of transmission and recurrence:

1. Vaccination:

   • Quadrivalent MenACWY conjugate vaccine (covers serogroups A, C, W, Y) administered at 12 months and booster at 5 years (per WHO 2022 schedule).
   • Serogroup B vaccine (4CMenB or MenB-FHbp) for high‑risk groups; not routinely given in all countries but recommended for infants in some regions.

2. Chemoprophylaxis for contacts (as described above) – reduces carriage and secondary cases by > 80 %.

3. Droplet isolation for the index case until 24 h after effective antibiotics.

4. Education of caregivers on early signs of meningitis and the importance of prompt medical attention.

5. Follow‑up audiology and neuro‑developmental screening at 1 month, 3 months, and 6 months post‑discharge to detect and intervene early on complications.

Key learning points

• Meningococcal meningitis classically presents with fever, neck stiffness, altered mental status, and a petechial or purpuric rash.
• CSF findings of high opening pressure, neutrophilic pleocytosis (>1 000 cells/µL), protein >1 g/L, and glucose <2.2 mmol/L (or CSF/serum ratio < 0.4) confirm bacterial meningitis.
• Immediate empiric therapy with ceftriaxone (± vancomycin) should be

More in Paediatrics

The patient is invented for teaching. AI-assisted study material for exam revision. Always confirm with standard textbooks and current guidelines; not medical advice.